Rigel Pharmaceuticals, Inc.
448 articles about Rigel Pharmaceuticals, Inc.
-
Rigel Announces Third Quarter 2015 Financial Results
11/4/2015
-
Rigel Announces Conference Call And Webcast To Report Third Quarter 2015 Financial Results
10/27/2015
-
Rigel And Aclaris Therapeutics Sign License Agreement For JAK Inhibitors To Treat Skin Disorders
9/9/2015
-
Aclaris Therapeutics Nabs $40 Million, Strikes Skin Disorders Pact with Rigel
9/9/2015
-
Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
9/8/2015
-
Rigel Announces Second Quarter 2015 Financial Results
8/5/2015
-
Rigel Announces Conference Call And Webcast To Report Second Quarter 2015 Financial Results
7/28/2015
-
Rigel Welcomes Keith A. Katkin To Board Of Directors
6/30/2015
-
Rigel To Present At Jefferies and Co. 2015 Global Healthcare Conference
5/28/2015
-
Rigel Announces First Quarter 2015 Financial Results
5/8/2015
-
Rigel Announces Conference Call And Webcast To Report First Quarter 2015 Financial Results And Pipeline Update
4/30/2015
-
Rigel Announces Fourth Quarter And Year End 2014 Financial Results
3/3/2015
-
Rigel Lands $339 Million+ Cancer Deal With Bristol-Myers Squibb
2/24/2015
-
Rigel Pharmaceuticals, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference
1/8/2015
-
Rigel Pharmaceuticals, Inc. Chairman And CEO James Gower Retires
11/24/2014
-
Rigel Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
11/4/2014
-
Rigel Pharmaceuticals, Inc. Experimental Eye Drug R348 Fails Mid-Stage Study
8/14/2014
-
Rigel Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
8/5/2014
-
Rigel Pharmaceuticals, Inc. Initiates Phase 3 Studies Of Fostamatinib In ITP
7/16/2014
-
Rigel Pharmaceuticals, Inc. To Present At Jefferies and Co. 2014 Global Healthcare Conference
5/29/2014